Dr. Reddy’s Laboratories Ltd ADR (RDY)

Name: Dr. Reddy’s Laboratories Ltd ADR (RDY) — تاریخچه صورتهای مالی
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

تاریخچه درآمد، سود و جریان نقد از صورت‌های مالی رسمی.

HEALTHCARE · وال‌استریت (آمریکا) · آخرین به‌روزرسانی: 2026-07-29

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.

شاخص‌های کلیدی

ارزش بازار: $10 billion
درآمد (سال مالی منتهی به 2026-03-31): ₹353.5B
سود خالص: ₹45.1B
حاشیه سود ناخالص: 52.8%
حاشیه سود خالص: 12.8%

نمودارهای تعاملی و صورت‌های مالی کامل ← مدل ارزش‌گذاری (DCF) ←

صورت سود و زیان سالانه

صورت سود و زیان	TTM → 2026-06-30	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31	2020-03-31	2019-03-31	2018-03-31	2017-03-31	2016-03-31	2015-03-31	2014-03-31	2013-03-31	2012-03-31	2011-03-31	2010-03-31	2009-03-31	2008-03-31	2007-03-31
مجموع درآمد	₹332.8B	₹353.5B	₹325.5B	₹279.2B	₹245.9B	₹214.4B	₹2.6B	₹174.6B	₹153.9B	₹142.0B	₹140.8B	₹154.7B	₹148.2B	₹132.2B	₹116.3B	₹96.7B	₹74.7B	₹70.3B	₹69.4B	₹50.0B	₹65.2B
سود ناخالص	₹166.9B	₹186.5B	₹190.4B	₹163.6B	₹139.3B	₹113.8B	₹1.3B	₹94.0B	₹83.4B	₹76.3B	₹78.4B	₹92.3B	₹85.4B	₹75.8B	₹60.6B	₹53.3B	₹40.3B	₹36.3B	₹36.5B	₹25.4B	₹30.9B
حاشیه سود ناخالص %	50.1%	52.8%	58.5%	58.6%	56.7%	53.1%	50.8%	53.8%	54.2%	53.7%	55.6%	59.7%	57.6%	57.4%	52.1%	55.1%	53.9%	51.7%	52.6%	50.8%	47.4%
سود عملیاتی (EBIT)	₹35.2B	₹48.9B	₹71.8B	₹67.7B	₹57.1B	₹29.5B	₹431M	₹16.0B	₹20.9B	₹11.9B	₹13.5B	₹29.6B	₹26.3B	₹26.0B	₹21.1B	₹18.3B	₹12.6B	₹2.0B	(₹2.8B)	₹3.4B	₹11.3B
حاشیه سود عملیاتی %	10.6%	13.8%	22.1%	24.3%	23.2%	13.8%	16.9%	9.2%	13.6%	8.4%	9.6%	19.1%	17.7%	19.7%	18.2%	18.9%	16.9%	2.9%	-4.1%	6.7%	17.2%
سود خالص	₹33.2B	₹45.1B	₹56.5B	₹55.7B	₹45.1B	₹23.6B	₹232M	₹19.5B	₹18.8B	₹9.8B	₹12.0B	₹20.0B	₹22.2B	₹21.5B	₹16.8B	₹14.3B	₹11.0B	₹1.1B	(₹5.2B)	₹4.7B	₹9.3B
حاشیه سود خالص %	10.0%	12.8%	17.4%	20.0%	18.3%	11.0%	9.1%	11.2%	12.2%	6.9%	8.6%	12.9%	15.0%	16.3%	14.4%	14.7%	14.8%	1.5%	-7.4%	9.4%	14.3%
EBITDA	₹55.6B	₹83.3B	₹96.7B	₹88.4B	₹74.4B	₹45.1B	₹535M	₹41.8B	₹35.5B	₹23.6B	₹24.8B	₹39.9B	₹34.4B	₹33.1B	₹22.5B	₹20.3B	₹16.8B	₹6.6B	₹1.5B	₹7.3B	₹14.3B
سود هر سهم (EPS)	₹39.81	₹54.11	₹67.77	₹66.80	₹54.17	₹28.34	₹0.28	₹23.48	₹22.62	₹11.80	₹14.42	₹23.40	₹25.95	₹25.21	₹19.69	₹16.76	₹12.99	₹1.26	₹-6.14	₹5.55	₹11.74
سهام منتشرشده (میلیون)	833M	833M	834M	834M	832M	832M	832M	830M	831M	831M	835M	855M	855M	853M	852M	851M	850M	848M	842M	843M	796M

منبع: گزارش‌های عمومی شرکت (SEC). پیش از اتکا به هر رقم، آن را در SEC EDGAR بررسی کنید.

ترازنامه‌ها، جریان‌های نقدی، داده‌های فصلی و نسبت‌های مالی کامل در نمایشگر تعاملی RDY در دسترس است. /companies/us/RDY

شرکت‌های مشابه

اطلاعات این وب‌سایت صرفاً برای اهداف آموزشی و اطلاع‌رسانی است و توصیه سرمایه‌گذاری نیست. هیچ هدف قیمتی یا توصیه‌ای منتشر نمی‌شود.

English version →همه سهام

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.